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Introduction
Functional behavior of breast cancer – repre-
senting underlying biology – can be analyzed
using MRI [1, 2]. The most widely used breast
MR imaging protocol is dynamic contrast-
enhanced T1-weighted imaging [3]. The cancer
enhances on dynamic contrast-enhanced MR
imaging because the contrast agent leaks from
the leaky vessels into the interstitial space. The
contrast agent subsequently leaks back into the
vascular space, creating a washout effect [4].
The normal parenchymal tissue of the breast
can also enhance after contrast injection. This
enhancement generally increases over time
[5]. Typically, a radiologist assesses this back-
ground parenchymal enhancement (BPE) using
the Breast Imaging Reporting and Data System
(BI-RADS) [6]. According to the BI-RADS, BPE
refers to the volume of enhancement and the
intensity of enhancement and is divided in four
incremental categories: minimal, mild, moder-
ate, and marked.
Researchers have developed semi-automatic
and automatic methods to extract properties of
BPE from MR images. For clarity, in this syl-
labus the BI-RADS definition will be referred to
as BPE, whereas the computer-extracted prop-
erties will not.
Both BPE and computer-extracted parenchy-
mal enhancement properties have been linked
to screening and diagnosis, hormone status
and age, risk of development of breast cancer,
response monitoring, and prognosis.
This work has been distributed as part of the syllabus
at the ISMRM Workshop on Breast MRI: Advancing the State
of the Art.
Background parenchymal
Enhancement
Giess et al. gave an exhaustive overview of the
appearance of BPE [5]. BPE has been shown
to be lower in older and in postmenopausal
women and patients [7–10].
In screening, MR images with high levels of
BPE were more likely to receive an abnormal
interpretation, which might lead to recommen-
dations for further testing [11–13]. Increased
BPE has also been associated with inaccurate
tumor size estimation and inaccurate tumor
staging [14, 15].
High BPE shows potential as a biomarker
for risk assessment of developing breast cancer
[16–20]. However, in women without a BRCA
mutation, this appeared to be confounded by
age [8]. In patients in whom a cancer is de-
tected, those with low BPE had a higher grade
tumor which is more likely to be progesterone
negative [21].
BPE generally decreases after systemic treat-
ment of breast cancer. This decrease in BPE
was found for anti-hormonal therapy [9,22–25],
chemotherapy [7,25], and radiation therapy [9].
A substantial agreement was found between
BPE assessment on dynamic contrast-enhanced
MRI and its counterpart on contrast-enhanced
mammography [9]. BPE also correlated with
uptake of 99mTc-methoxy isobutyl isonitrile in
the breast [26]. BPE did, however, not appear
to be related to 18F-fludeoxyglucose uptake on
positron emission tomography [27].
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Computer-extracted parenchymal
enhancement
Computer-extracted features of parenchymal
enhancement are typically generated using the
following workflow: The parenchymal tissue
is segmented on the MR images after which
features are calculated using these segmented
voxels.
In semi-automatic methods, several ap-
proaches exist. Examples include manual de-
lineation of parenchymal tissue on the MR im-
ages by an expert and growing of parenchymal
tissue segmentations from user-selected seed
points. In automatic methods, computer algo-
rithms perform all the steps necessary to get to
a parenchymal tissue segmentation (Figure 1).
Once the parenchymal tissue is segmented,
numerous features can be calculated. Some
common features include the percent enhance-
ment, the signal enhancement ratio, or texture
features.
Analogous to BPE, these computer-extracted
features can serve as biomarker for the risk
of developing breast cancer. They often are
often used, however, as biomarkers for differ-
ent tasks such as tumor recurrence, response
to treatment, or patient survival. Examples of
these biomarkers and their applications can be
found in Table 1.
Example: CPE as biomarker of
survival
An example of such a biomarker from our
group is contralateral parenchymal enhance-
ment (CPE) [28]. In a cohort of 398 patients
with estrogen receptor (ER)-positive/HER2-
negative breast cancer from the Netherlands
Cancer Institute in Amsterdam, we found that
patients who have high enhancement in the
parenchyma of the contralateral breast (i.e.
high CPE) have a significantly better survival
than patients with low CPE. This was indepen-
dent of potential confounding variables such as
patient age and tumor pathology markers [28].
The CPE biomarker was validated in an
independent cohort of 302 patients with ER-
positive/HER2-negative breast cancer from the
Memorial Sloan Kettering Cancer Center in
New York [29].
In patients considered to be at high-risk by
molecular assays such as the 70-gene signature
and the 21-gene recurrence score, CPE could
identify a group of patients at relatively low
risk [30].
Outlook
BPE and computer extracted features of
parenchymal enhancement show substantial
potential as biomarkers for breast cancer of di-
agnosis, response monitoring, prognosis, and
many other clinically relevant tasks. There are,
however, still several opportunities to further
progress the field, especially for the computer-
extracted biomarkers. Before these can be used
at large scale, some issues should be addressed.
The computer-extracted biomarkers should
be made agnostic to deviations to MR imaging
vendors and protocols, since imaging param-
eters could influence the biomarkers. Image
analysis methods must produce similar results
across vendors and protocols. Recent advances
in machine learning and most notably deep
learning show potential for this. For exam-
ple, in a recent MICCAI challenge on brain
white matter lesion segmentation, deep learn-
ing algorithms showed excellent performance
on images from scanners that the algorithms
were not trained on (http://wmh.isi.uu.nl).
The biology of these computer-extracted
biomarkers should be better understood, e.g.
by analyzing radiogenomic or radioproteomic
datasets. These ’multi-omic’ datasets can even
be used for better prediction of disease out-
come. An example of this approach com-
bined MR imaging features of tumor and
parenchyma with genomic data to find mul-
tidimensional clusters related to patient sur-
vival [31].
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Figure 1: Example of an automatic image analysis pipeline for calculation of parenchymal enhancement features. A:
Transversal pre-contrast breast MRI scan. B: The breast area is automatically segmented. C: The parenchymal
tissue in each breast is segmented. D: The enhancement of the parenchymal tissue between the pre-contrast
scan and the first post-contrast scan. On these voxels, features are typically calculated.
Table 1: Examples of computer-extracted parenchymal enhancement biomarkers. NB This list is not meant to be
exhaustive.
Authors Year Parenchyma features Clinical endpoint
Aghaei et al. [32] 2015 Bilateral PE Complete reponse scored on RECIST
Fan et al. [33] 2017 Bilateral PE Complete reponse scored on RECIST
Hattangadi et al. [34] 2008 SER surrounding the tumor Disease-free survival after NAC
Jones et al. [35] 2013 PE surrounding the tumor Disease-free survival after NAC
Kim et al. [36] 2013 SER surrounding the tumor Ipsilateral breast tumor recurrence
Knuttel et al. [37] 2016 SER surrounding the tumor Extensive ductal carcinoma in situ
Luo et al. [38] 2017 Functional Tumor Volume, SER, PE DCIS recurrence after treatment
Nabavizadeh et al. [39] 2011 PE surrounding the tumor Microvessel density, genomic changes
van der Velden et al. [28] 2015 Contralateral PE Overall and disease-free survival
van der Velden et al. [29] 2018 Contralateral PE Overall and disease-free survival validation
van der Velden et al. [30] 2017 Contralateral PE Complementary value to 70-GS and 21-GRS
Wang et al. [40] 2015 Density, enhancement, texture Triple-negative status tumor
Wu et al. [41] 2015 FGT volume and PE Breast cancer risk after RRSO
Wu et al. [42] 2016 Wash-in slope variance and SER Breast cancer risk
You et al. [43] 2017 Contralateral PE change Pathological complete remission after NAC
70-GS = 70-gene signature, 21-GRS = 21-gene recurrence score, DCIS = ductal carcinoma in situ, FGT = fibroglandular
tissue, NAC = neoadjuvant chemotherapy, PE = percent enhancement, RECIST = response evaluation criteria in solid
tumors, RRSO = risk-reducing salpingo-oophorectomy, SER = signal enhancement ratio
3
Conclusion
BPE and computer extracted features of
parenchymal enhancement show potential as
biomarkers for clinically relevant tasks.
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